GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
Friday, January 13, 2023 12:30 - 1:30 PM CT
Monday, January 26, 2023 7:00 - 8:00 PM CT
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians – prescribed AAFP Credit(s)
  • Physicians/ABIM MOC – ABIM MOC Point(s)
  • Physician Assistants – AAPA Category 1 CME
  • Nurse Practitioners – contact hour(s) of continuing education

PROGRAM OVERVIEW

In T2DM there is a combination of reduced insulin production and secretion and insulin resistance. One cause of decreased insulin secretion is an impaired response to glucose-stimulated release of glucagon-like peptide 1 (GLP-1). Endogenous GLP-1 has multiple physiologic effects but is short-lived. GLP-1 receptor analogues (RAs) have a longer half-life, retain bioactivity, and have benefits beyond glycemic management, including mediating satiety; causing weight loss; and favorable cardiovascular,  hepatic, and renal effects.

Based on the wide-ranging beneficial effects of GLP-1 RAs, the management of T2DM is no longer based on glucose control alone. The most recent ADA guidelines for T2DM provide guidance on drug- and patient-specific factors to consider when selecting an antihyperglycemic agent and therapeutic algorithms that center on a patient’s cardiovascular and renal profiles.

GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM will inform clinicians about the pleiotropic effects of GLP-1 RAs, the demonstrated clinical efficacy of these agents for managing patients with T2DM and a variety of comorbid conditions, and guideline recommendations for incorporating GLP-1 RAs into management strategies for T2DM.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Novo Nordisk.

RELATED COURSES

Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy

Learn More

Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes

Learn More

Advances in Cancer Screening and Detection: What PCPs Need to Know

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy